Author

Elisia Villemure

GenentechORCID 0000-0002-0902-5189Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1

Frequent Co-Authors

Aaron LictaoiD· 1 shared Anna ShemorryiD· 1 shared Benjamin T. WaltersiD· 1 shared Brett M. BabiniD· 1 shared Bridget Hoag· 1 shared Caroline L. GilchristiD· 1 shared Carrie R. GraveeliD· 1 shared Curt J. EssenburgiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaron LictaoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases

Anna Shemorry, Willem den Besten, Melinda M. Mulvihill, Curt J. Essenburg, Nicole Blaquière, Tracy Kleinheinz, Elisia Villemure, Frank Peale, Gauri S. Deshmukh, Danilo Maddalo, Elizabeth Levy, Kebing Yu, Matthew R. Steensma, Elizabeth A. Tovar, Emily Wolfrum, , Ingrid E. Wertz

This study evaluates bifunctional ER degraders with different ubiquitin ligase ligands, finding that pan-IAP antagonists enhance ER degradation and induce TNF-dependent cell death more effectively than existing therapies.

Cell chemical biology · May 1, 2025Peer-reviewedCancer Biology

Rational design of potent small molecule SMARCA2/A4 (BRM/BRG1) degraders acting via the recruitment of FBXO22

Elisia Villemure, Robert L. Yauch, Joachim Rudolph, Tom Januario, Mingshuo Zeng, Hanna G. Budayeva, Benjamin T. Walters, Aaron Lictao, Sherry K. Li, Xiaofen Ye, Caroline L. Gilchrist, Bridget Hoag, Nicholas Endres, Peter Hsu, John Chan, , Joyce Liu

This paper identifies a potent and specific SMARCA2/A4 degrader, G-6599, which works via FBXO22 recruitment and covalent conjugation, offering therapeutic potential.

bioRxiv · Mar 5, 2025 · PreprintCancer Biology